Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 30;22(2):6.
doi: 10.1007/s11894-020-0744-z.

The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care

Jonathan A Beard  1 , Diana L Franco  1 , Benjamin H Click  2
Affiliations
Review

The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care

Jonathan A Beard et al. Curr Gastroenterol Rep. .

Abstract

Purpose of review: To examine the quantifiable economic impact of inflammatory bowel disease (IBD), key cost drivers and determinants, and the impact of value-based care in IBD. Finally, we prognosticate on future directions and opportunities on healthcare economics in IBD.

Recent findings: New value-based initiatives, technologically driven interventions, and quality improvement programs have demonstrated reductions in healthcare utilization and enhanced patient outcomes, and several have realized cost of care reductions. IBD is a costly, chronic illness with unbalanced spending by a small proportion of individuals. Pharmaceutical costs are overtaking inpatient expenses as the primary cost driver. Value-based care initiatives including the IBD medical home, remote monitoring platforms such as myIBDcoach and Project Sonar, and learning healthcare networks exemplified by ImproveCareNow have all demonstrated successes in improving care quality, patient outcomes, and reduced healthcare spending in some populations. The future of value-based care in IBD is bright, with ample opportunities for model refinement, collaboration, and growth.

Keywords: Biologics; Cost; Donabedian; Inflammatory bowel disease; Patient-centered medical home; Quality; Specialty medical home; Value-based care.

PubMed Disclaimer

References

    1. J Crohns Colitis. 2018 Mar 28;12(4):408-418 - PubMed
    1. J Clin Gastroenterol. 2006 Mar;40(3):200-8 - PubMed
    1. Can J Gastroenterol Hepatol. 2014 May;28(5):275-85 - PubMed
    1. Inflamm Bowel Dis. 2011 Jan;17(1):450-7 - PubMed
    1. Arch Med Sci. 2016 Apr 1;12(2):295-302 - PubMed

MeSH terms